riboflavin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases erythrocyte glutathione reductase activation coefficient (EGRac)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Riboflavin supplementation significantly decreased plasma tHcy (P=0.005) and EGRAC (P=0.014), but not plasma ferritin, uric acid or C-reactive protein.”
Quoted verbatim from Riboflavin supplementation and biomarkers of cardiovascular disease in the elderly.. - Study
- RCT
- Participants
- 42
- Duration
- 4 weeks
- Dose
- 10 mg riboflavin per day orally vs placebo
- Population
- Portuguese elderly people aged 60-94 years with low riboflavin status (EGRAC of 1.2 or more) attending day social centres
Riboflavin supplementation and biomarkers of cardiovascular disease in the elderly.2009PMID:19390751Permalink
Keep reading
- Everything the graph holds on riboflavin
- Every compound studied against Erythrocyte glutathione reductase activation coefficient (EGRac)
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PAP8PGVATQ6588EKQZSD5S